The biopharmaceutical company reports that its Saphnelo treatment met the primary endpoint in a Phase III trial for systemic lupus erythematosus, demonstrating a statistically significant and clinically meaningful reduction in disease activity.
The pharmaceutical company's trial of a drug for COPD did not meet its primary endpoint, though it showed some numerical improvement.
The pharmaceutical company has issued a notification regarding a previous shareholding disclosure that was provided in error.
The pharmaceutical company has received notification of a change in shareholding by The Capital Group Companies, Inc.
The pharmaceutical company has received notification of a change in shareholding by The Capital Group Companies, Inc.
The pharmaceutical company has disclosed a sale of ordinary shares by its Chief Financial Officer.
The pharmaceutical company has received notification of a change in major shareholding.
The healthcare company has reported a change in major shareholding, with The Capital Group Companies, Inc. reducing its stake in the firm.
The biopharmaceutical giant reported an 11% increase in total revenue and a 16% rise in core earnings per share for H1 2025, backed by strong performance across all major regions and positive pipeline developments.
The biopharmaceutical company announced that its novel nanobody treatment for a rare autoimmune disorder met primary and secondary endpoints in a Phase III trial.